Can Intel’s Apple Deal Rewrite the Foundry Story?

NEW YORK — Intel opened Monday at $111.93 and immediately ran toward $130 on a Wall Street Journal report that the chipmaker has reached a preliminary agreement to manufacture chips for Apple devices — a single headline that forced a rethink of Intel’s foundry ambitions and sent the stock on the most meaningful move it has logged in months.

A Cautious Open Beneath a Recovering Tape

The S&P 500 opened Monday down 0.12% and the Nasdaq slipped 0.34% at the bell, a muted continuation of Friday’s 0.8% and 1.7% respective gains. By mid-morning both indices had recovered, with the S&P 500 edging to 7,410.35 — up 0.15% — and the Nasdaq at 26,260.04. The Russell 2000 outperformed at the open, gaining 0.76%, a signal that risk appetite is not absent, just concentrated. The Dow opened roughly flat.

The early read is a market digesting last week’s gains rather than extending them aggressively. As we covered in last week’s analysis of the S&P 500 at 7,400, this level was always going to be a test, and this morning’s open confirmed it. The question now is whether single-stock catalysts — Intel most visibly — can substitute for a broader macro tailwind while inflation data and Fed rhetoric continue to weigh on the background.

Small-cap outperformance at the open is worth watching as a tell. When the Russell leads the Nasdaq lower, it typically signals rotation out of high-multiple names. When it leads to the upside on a day the Nasdaq opens negative, it often signals that the selling in megacap tech is idiosyncratic rather than systemic.

Data Visual

Opening Bell Movers — First-Session % Change, May 11, 2026

Compares the opening percentage moves of the session’s primary movers against major index opens, giving traders an instant read on relative strength and risk appetite.

Values in %

Intel’s Apple Catalyst — What the Price Action Actually Says

Intel’s session range of $111.84 to $130.57 against an opening print of $111.93 is a trader’s tell: the stock gapped violently at the open and volume came in fast, with 52.59 million shares trading against a 170.62 million daily average. That ratio — roughly 31% of average volume in the first hours — is not the blowout institutional accumulation some might read it as. It could as easily reflect short-covering and retail momentum chasing as genuine conviction buying from large funds.

The Intel-Apple narrative is compelling on the surface. Apple’s move toward custom silicon, combined with its stated interest in domestic chip sourcing, theoretically makes Intel Foundry Services a viable partner. Intel also delivered a Q1 earnings beat that has largely been forgotten in the Apple excitement: adjusted EPS of $0.29 against a consensus estimate of $0.01, with revenue of $13.58 billion clearing the $12.32 billion bar. Those numbers matter independently of any Apple deal and represent genuine execution progress under Intel’s restructured management.

Still, traders should hold their enthusiasm against one stubborn fact: the Wall Street analyst community has not bought the Intel recovery story in size. The consensus price target sits near $79 — roughly 40% below the current session high — backed by 30 Hold ratings, 5 Sells, and only 13 Buys. BofA raised its target to $96 from $56 this morning but kept its Underperform rating. When a bank raises a target by 71% and still says sell, the signal is not bullish — it is a reluctant acknowledgment that the short thesis is getting squeezed, not abandoned.

Data Visual

Intel (INTC) Session Price Range vs. Key Analyst Targets — May 11, 2026

Shows Intel’s intraday trading range alongside Wall Street consensus and BofA price targets, helping traders gauge where the stock sits relative to professional estimates.

Values in $

Moderna’s Hantavirus Trade — Opportunity or Overreach

Moderna surged from an intraday low of $48.78 to $57.78 — a 15.5% intraday swing — after disclosing it had already been developing a hantavirus vaccine before the outbreak aboard the MV Hondius cruise ship. At least nine confirmed or suspected cases have been reported, with three fatalities among passengers evacuated to Omaha, Nebraska, on a chartered aircraft this morning.

Volume told the real story: 20.93 million shares traded against an average of 7.77 million — nearly 2.7 times normal volume — which signals this move is not purely algorithmic headline-chasing. Retail and institutional money both moved. For context, Moderna’s 52-week range spans $22.28 to $59.55, meaning this spike brought the stock near its yearly peak on a single news event tied to a disease with limited mass-market vaccine potential compared to COVID-19.

That comparison is the contrarian caution flag. Hantavirus is not a pandemic-scale respiratory illness. The market for a hantavirus vaccine, even if Moderna advances it, is a fraction of the COVID market that built the company’s valuation. The BofA analyst Alex Stranahan raised Moderna’s price target to $32 from $31 — well below today’s $56 print — while keeping an Underperform rating. The consensus 12-month target is $36.82, implying the Street sees roughly 35% downside from current levels. Traders playing this move for a sustained re-rating should weigh that gap carefully. As we noted in our look at healthcare momentum trades this year, biotech spikes on disease-specific catalysts frequently give back gains within days once the headline news cycle rotates.

Dollar General’s Quiet Warning for Consumer Stocks

Away from the headline fireworks, Dollar General’s 5.8% decline deserves attention for what it says about the broader consumer picture. The company’s FY2026 guidance calls for same-store sales growth of 2.2%–2.7% and EPS of $7.10–$7.35 — figures soft enough to disappoint a market that had expected more after a Q1 beat of $1.93 against the $1.57 consensus. A leadership transition layered on top of cautious guidance is the kind of double uncertainty that institutional holders typically exit, not hold through.

Dollar General serves as a real-time read on the low-income consumer. When a discount retailer with tailwind exposure to budget-constrained shoppers guides conservatively, it suggests the consumer spending base is not expanding into the second half of the year. That matters for the inflation and consumer spending debate that has defined equity positioning through much of 2026.

The Levels That Determine the Next Hour’s Direction

With the S&P 500 hovering just above 7,400 and the Nasdaq recovering from its opening dip, the first hour’s price action is a negotiation between the Intel and Moderna single-stock euphoria and a broader tape that lacks a macro catalyst to extend Friday’s gains. Nebius Group also warrants attention ahead of its Q1 2026 earnings Wednesday, with shares near a recent all-time high backed by a $2 billion Nvidia partnership and a planned $643 million Eigen AI acquisition. The chip sector’s broader positioning heading into Wednesday will shape how that report lands.

The opening hour leaves traders with a split screen. Intel is trading a story Wall Street analysts broadly do not endorse at current prices, Moderna is running toward a structural ceiling against skeptical price targets, and Dollar General is flashing a quiet consumer warning the broader indices are not yet pricing. The S&P 500 holding above 7,399 through the first hour would be the minimum condition to call this session constructive. A slip below that level, particularly if Intel fades from its session high, would reframe Monday as a fade-the-gap day rather than a trend extension.